The latest

News

aikium

Tenant Spotlight on Aikium: A Trillion Shots at Targeting Tangled Proteins

Aikium has essentially invented a new protein family. Called “SeqR” proteins, they are sequence specific binders that can be applied to different therapeutic needs such as cancer, neuro-inflammation, and some autoimmune disorders. Aikium is going after chemokine receptors, a subset of G-protein coupled receptors, a large class of molecules that have long proven difficult to target. By virtue of being on immune cells, they are front and center in cancer and immune-mediated diseases.
―

Latest news140

Aerial view of BBH

Bakar BioEnginuity Hub Raises the Bar for Urban Adaptive Reuse Projects

“The original building structural design is kind of a house of cards,” says Allen Nudel, director of business strategy at Forell/Elsesser who led the structural team. “It’s an awe-inspiring and beautiful icon of innovation, and one of the most architecturally complicated structures in the Bay Area—maybe in the entire western United States. It was by far the most difficult seismic retrofit we’ve ever done.” Read post
A view of the skylights at BBH

A Brutalist Icon in Berkeley Is Reborn as a Bioresearch Hub

“I still can’t believe that I was able to work on the building, be part of the legacy,” said Kevin Koblik, project manager for MBH Architects, the firm that headed the conversion effort. “It was a challenge start to finish, but in all the right ways.” Read post
An interior view of BBH's skylights

A First Look Inside UC Berkeley’s Bakar BioEnginuity Hub

“We always intended Bakar Labs to have a ‘double bottom line,’ a responsibility to select and support startups that have a strong chance of market success and are developing solutions to make the world a better place,” said Regis Kelly, director of Bakar Labs and QB3 executive director. Read post